{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T20:38:26Z","timestamp":1759178306925,"version":"3.37.3"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,6,9]],"date-time":"2018-06-09T00:00:00Z","timestamp":1528502400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2018,6,9]],"date-time":"2018-06-09T00:00:00Z","timestamp":1528502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s12325-018-0721-1","type":"journal-article","created":{"date-parts":[[2018,6,9]],"date-time":"2018-06-09T11:17:29Z","timestamp":1528543049000},"page":"1087-1102","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Development of a Comprehensive Dataset of Hepatitis C Patients and Examination of Disease Epidemiology in the United States, 2013\u20132016"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9480-0580","authenticated-orcid":false,"given":"Viktor V.","family":"Chirikov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven E.","family":"Marx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shivaji R.","family":"Manthena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Strezewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sammy","family":"Saab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,9]]},"reference":[{"issue":"1","key":"721_CR1","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/hep.27259","volume":"61","author":"JP Messina","year":"2015","unstructured":"Messina JP, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61(1):77\u201387.","journal-title":"Hepatology"},{"issue":"6","key":"721_CR2","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1002\/hep.26218","volume":"57","author":"H Razavi","year":"2013","unstructured":"Razavi H, et al. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology. 2013;57(6):2164\u201370.","journal-title":"Hepatology"},{"issue":"1 Suppl","key":"721_CR3","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1016\/j.jhep.2014.07.012","volume":"61","author":"RH Westbrook","year":"2014","unstructured":"Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol. 2014;61(1 Suppl):S58\u201368.","journal-title":"J Hepatol"},{"issue":"10","key":"721_CR4","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1093\/cid\/ciw111","volume":"62","author":"KN Ly","year":"2016","unstructured":"Ly KN, et al. Rising mortality associated with hepatitis C virus in the United States, 2003\u20132013. Clin Infect Dis. 2016;62(10):1287\u20138.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"721_CR5","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1002\/hep.28571","volume":"64","author":"J Chhatwal","year":"2016","unstructured":"Chhatwal J, et al. Hepatitis C disease burden in the United States in the era of oral direct-acting antivirals. Hepatology. 2016;64(5):1442\u201350.","journal-title":"Hepatology"},{"issue":"12","key":"721_CR6","doi-asserted-by":"publisher","first-page":"895","DOI":"10.7326\/M17-0766","volume":"166","author":"GJ Buckley","year":"2017","unstructured":"Buckley GJ, Strom BL. A national strategy for the elimination of viral hepatitis emphasizes prevention, screening, and universal treatment of hepatitis C. Ann Intern Med. 2017;166(12):895\u20136.","journal-title":"Ann Intern Med"},{"key":"721_CR7","unstructured":"US Centers for Disease Control and Prevention. National viral hepatitis action plan. 2017. https:\/\/www.hhs.gov\/sites\/default\/files\/National%20Viral%20Hepatitis%20Action%20Plan%202017-2020.pdf. Accessed 24 Oct 2017."},{"key":"721_CR8","unstructured":"World Health Organization. Combating hepatitis B and C to reach elimination by 2030. 2016; http:\/\/www.who.int\/hepatitis\/publications\/hep-elimination-by-2030-brief\/en\/. Accessed 8 May 2018."},{"key":"721_CR9","doi-asserted-by":"crossref","unstructured":"Mehta D, Mccombs J, Sanchez Y, Marx S, Saab S. Effectiveness of hepatitis C virus screening laws in United States: evidence from paid claims data from 2010 to 2016. In: The International Liver Congress. 2018. Paris, France.","DOI":"10.1016\/S0168-8278(18)30566-X"},{"issue":"1","key":"721_CR10","doi-asserted-by":"publisher","first-page":"12326","DOI":"10.1038\/s41598-017-10190-8","volume":"7","author":"N Islam","year":"2017","unstructured":"Islam N, et al. Hepatitis C cross-genotype immunity and implications for vaccine development. Sci Rep. 2017;7(1):12326.","journal-title":"Sci Rep"},{"key":"721_CR11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/IJGM.S127689","volume":"10","author":"NJ Burstow","year":"2017","unstructured":"Burstow NJ, et al. Hepatitis C treatment: where are we now? Int J Gen Med. 2017;10:39\u201352.","journal-title":"Int J Gen Med"},{"issue":"Suppl 1","key":"721_CR12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/liv.13027","volume":"36","author":"T Asselah","year":"2016","unstructured":"Asselah T, et al. Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. Liver Int. 2016;36(Suppl 1):47\u201357.","journal-title":"Liver Int"},{"key":"721_CR13","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.coph.2017.10.001","volume":"37","author":"N Alkhouri","year":"2017","unstructured":"Alkhouri N, Lawitz E, Poordad F. Novel treatments for chronic hepatitis C: closing the remaining gaps. Curr Opin Pharmacol. 2017;37:107\u201311.","journal-title":"Curr Opin Pharmacol"},{"key":"721_CR14","doi-asserted-by":"crossref","unstructured":"Gane E et al. High efficacy of ABT-493 and ABT-530 treatment in patients with HCV genotype 1 or 3 infection and compensated cirrhosis. Gastroenterology. 2016;151(4):651\u2013659.e1.","DOI":"10.1053\/j.gastro.2016.07.020"},{"issue":"1","key":"721_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/17474124.2018.1411802","volume":"12","author":"H Hubbard","year":"2018","unstructured":"Hubbard H, Lawitz E. Glecaprevir\u2009+\u2009pibrentasvir (ABT493\u2009+\u2009ABT-530) for the treatment of Hepatitis C. Expert Rev Gastroenterol Hepatol. 2018;12(1):9\u201317.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"2","key":"721_CR16","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jhep.2017.03.039","volume":"67","author":"PY Kwo","year":"2017","unstructured":"Kwo PY, et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1\u20136 without cirrhosis. J Hepatol. 2017;67(2):263\u201371.","journal-title":"J Hepatol"},{"issue":"6","key":"721_CR17","first-page":"e224","volume":"22","author":"X Yao","year":"2016","unstructured":"Yao X, et al. Adoption of new agents and changes in treatment patterns for hepatitis C: 2010-2014. Am J Manag Care. 2016;22(6):e224\u201332.","journal-title":"Am J Manag Care"},{"key":"721_CR18","unstructured":"American Association for the Study of Liver Disease and Infectious Disease Society of America. HCV guidance: recommendations for testing, managing, and treating hepatitis C. 2017. https:\/\/www.hcvguidelines.org\/sites\/default\/files\/full-guidance-pdf\/HCVGuidance_September_21_2017_f.pdf. Accessed 24 Jan 2018."},{"key":"721_CR19","unstructured":"Centers for Disease Control and Prevention. Viral hepatitis surveillance, United States, 2015. 2015; https:\/\/www.cdc.gov\/hepatitis\/statistics\/2015surveillance\/pdfs\/2015HepSurveillanceRpt.pdf. Accessed 24 Oct 2017."},{"issue":"6","key":"721_CR20","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/S1473-3099(16)00124-9","volume":"16","author":"JB Joy","year":"2016","unstructured":"Joy JB, et al. The spread of hepatitis C virus genotype 1a in North America: a retrospective phylogenetic study. Lancet Infect Dis. 2016;16(6):698\u2013702.","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"721_CR21","doi-asserted-by":"publisher","first-page":"705","DOI":"10.7326\/0003-4819-144-10-200605160-00004","volume":"144","author":"GL Armstrong","year":"2006","unstructured":"Armstrong GL, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144(10):705\u201314.","journal-title":"Ann Intern Med"},{"issue":"5","key":"721_CR22","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/hep.27978","volume":"62","author":"BR Edlin","year":"2015","unstructured":"Edlin BR, et al. Toward a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology. 2015;62(5):1353\u201363.","journal-title":"Hepatology"},{"issue":"5","key":"721_CR23","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1080\/03007995.2017.1288613","volume":"33","author":"A Goolsby Hunter","year":"2017","unstructured":"Goolsby Hunter A, et al. Clinical characteristics, healthcare costs, and resource utilization in hepatitis C vary by genotype. Curr Med Res Opin. 2017;33(5):829\u201336.","journal-title":"Curr Med Res Opin"},{"key":"721_CR24","unstructured":"CDA Foundation. Polaris Observatory. http:\/\/polarisobservatory.org\/polaris_view\/hepC.htm. Accessed 7 Dec 2017."},{"key":"721_CR25","unstructured":"Emory University, Rollins School of Public Health, in partnership with Gilead Sciences, Inc. HepVu. https:\/\/hepvu.org\/. Accessed 7 Dec 2017."},{"issue":"11","key":"721_CR26","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1093\/cid\/cix202","volume":"64","author":"ES Rosenberg","year":"2017","unstructured":"Rosenberg ES, et al. Estimation of state-level prevalence of hepatitis C virus infection, US States and District of Columbia, 2010. Clin Infect Dis. 2017;64(11):1573\u201381.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"721_CR27","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/jvh.12248","volume":"21","author":"H Razavi","year":"2014","unstructured":"Razavi H, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today\u2019s treatment paradigm. J Viral Hepat. 2014;21(Suppl 1):34\u201359.","journal-title":"J Viral Hepat"},{"issue":"4","key":"721_CR28","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/ofid\/ofy065","volume":"5","author":"JK Cornett","year":"2018","unstructured":"Cornett JK, et al. Results of a hepatitis C virus screening program of the 1945\u20131965 birth cohort in a large emergency department in New Jersey. Open Forum Infect Dis. 2018;5(4):5.","journal-title":"Open Forum Infect Dis"},{"issue":"Suppl 2","key":"721_CR29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/00333549161310S202","volume":"131","author":"G Ramirez","year":"2016","unstructured":"Ramirez G, et al. Early identification and linkage to care for people with chronic HBV and HCV infection: the HepTLC Initiative. Public Health Rep. 2016;131(Suppl 2):5\u201311.","journal-title":"Public Health Rep"},{"issue":"3","key":"721_CR30","doi-asserted-by":"publisher","first-page":"09","DOI":"10.1093\/ofid\/ofx109","volume":"4","author":"M Castrejon","year":"2017","unstructured":"Castrejon M, et al. Implementation of a large system-wide hepatitis C virus screening and linkage to care program for baby boomers. Open Forum Infect Dis. 2017;4(3):09.","journal-title":"Open Forum Infect Dis"},{"key":"721_CR31","unstructured":"Merck Manual. Fibrosis of the liver. https:\/\/www.merckmanuals.com\/home\/liver-and-gallbladder-disorders\/fibrosis-and-cirrhosis-of-the-liver\/fibrosis-of-the-liver. Accessed 10 Jan 2018."},{"issue":"6","key":"721_CR32","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling RK, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology. 2006;43(6):1317\u201325.","journal-title":"Hepatology"},{"issue":"3","key":"721_CR33","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/hep.24105","volume":"53","author":"ZH Lin","year":"2011","unstructured":"Lin ZH, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 2011;53(3):726\u201336.","journal-title":"Hepatology"},{"key":"721_CR34","unstructured":"Malkina A. Merck Manual. Chronic kidney disease. https:\/\/www.merckmanuals.com\/professional\/genitourinary-disorders\/chronic-kidney-disease\/chronic-kidney-disease. Accessed 1 Feb 2018."},{"key":"721_CR35","doi-asserted-by":"publisher","unstructured":"Gordon SC et al. Race, age, and geography impact hepatitis C genotype distribution in the United States. J Clin Gastroenterol. 2017. https:\/\/doi.org\/10.1097\/MCG.0000000000000872.","DOI":"10.1097\/MCG.0000000000000872"},{"issue":"8","key":"721_CR36","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrgastro.2015.97","volume":"12","author":"AS Perelson","year":"2015","unstructured":"Perelson AS, Guedj J. Modelling hepatitis C therapy-predicting effects of treatment. Nat Rev Gastroenterol Hepatol. 2015;12(8):437\u201345.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"721_CR37","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1002\/hep.27750","volume":"61","author":"MA Konerman","year":"2015","unstructured":"Konerman MA, et al. Improvement of predictive models of risk of disease progression in chronic hepatitis C by incorporating longitudinal data. Hepatology. 2015;61(6):1832\u201341.","journal-title":"Hepatology"},{"issue":"11","key":"721_CR38","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1038\/ajg.2013.332","volume":"108","author":"AG Singal","year":"2013","unstructured":"Singal AG, et al. Machine learning algorithms outperform conventional regression models in predicting development of hepatocellular carcinoma. Am J Gastroenterol. 2013;108(11):1723\u201330.","journal-title":"Am J Gastroenterol"},{"key":"721_CR39","doi-asserted-by":"crossref","unstructured":"Chirikov VV et al. Tree-based claims algorithm for measuring pretreatment quality of care in Medicare disabled hepatitis C patients. Med Care. 2017;55(12):e104\u2013e112.","DOI":"10.1097\/MLR.0000000000000405"},{"issue":"7","key":"721_CR40","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.cgh.2016.03.040","volume":"14","author":"V Lo Re 3rd","year":"2016","unstructured":"Lo Re V 3rd, et al. Disparities in absolute denial of modern hepatitis C therapy by type of insurance. Clin Gastroenterol Hepatol. 2016;14(7):1035\u201343.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"721_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jcv.2017.01.007","volume":"89","author":"AC Moorman","year":"2017","unstructured":"Moorman AC, Drobenuic J, Kamili S. Prevalence of false-positive hepatitis C antibody results, National Health and Nutrition Examination Study (NHANES) 2007\u20132012. J Clin Virol. 2017;89:1\u20134.","journal-title":"J Clin Virol"},{"issue":"38","key":"721_CR42","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.15585\/mmwr.mm6638a3","volume":"66","author":"CA Flanigan","year":"2017","unstructured":"Flanigan CA, et al. Evaluation of the impact of mandating health care providers to offer hepatitis C virus screening to all persons born during 1945\u20131965\u2014New York, 2014. MMWR Morb Mortal Wkly Rep. 2017;66(38):1023\u20136.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"Suppl 2","key":"721_CR43","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1177\/00333549161310S205","volume":"131","author":"C Jorgensen","year":"2016","unstructured":"Jorgensen C, Carnes CA, Downs A. Know more hepatitis: CDC\u2019s national education campaign to increase hepatitis C testing among people born between 1945 and 1965. Public Health Rep. 2016;131(Suppl 2):29\u201334.","journal-title":"Public Health Rep"},{"issue":"10","key":"721_CR44","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1093\/cid\/ciu643","volume":"59","author":"AG Suryaprasad","year":"2014","unstructured":"Suryaprasad AG, et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006\u20132012. Clin Infect Dis. 2014;59(10):1411\u20139.","journal-title":"Clin Infect Dis"},{"issue":"17","key":"721_CR45","first-page":"453","volume":"64","author":"JE Zibbell","year":"2015","unstructured":"Zibbell JE, et al. Increases in hepatitis C virus infection related to injection drug use among persons aged\u2009\u2264\u200930\u00a0years\u2014Kentucky, Tennessee, Virginia, and West Virginia, 2006\u20132012. MMWR Morb Mortal Wkly Rep. 2015;64(17):453\u20138.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"721_CR46","unstructured":"Center for Behavioral Health Statistics and Quality. 2015 national survey on drug use and health: detailed tables. Rockville: Substance Abuse and Mental Health Services Administration; 2016."},{"issue":"Suppl 2","key":"721_CR47","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1177\/00333549161310S214","volume":"131","author":"NA Blackburn","year":"2016","unstructured":"Blackburn NA, Patel RC, Zibbell JE. Improving screening methods for hepatitis C among people who inject drugs: findings from the HepTLC Initiative, 2012\u20132014. Public Health Rep. 2016;131(Suppl 2):91\u20137.","journal-title":"Public Health Rep"},{"issue":"Suppl 2","key":"721_CR48","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1177\/00333549161310S203","volume":"131","author":"RC Patel","year":"2016","unstructured":"Patel RC, Vellozzi C, Smith BD. Results of hepatitis C birth-cohort testing and linkage to care in selected U.S. sites, 2012\u20132014. Public Health Rep. 2016;131(Suppl 2):12\u20139.","journal-title":"Public Health Rep"},{"key":"721_CR49","unstructured":"National Academies of Sciences, Engineering, and Medicine. Big data and analytics for infectious disease research, operations, and policy: proceedings of a workshop. 2016, Washington DC: The National Academies Press."},{"issue":"9","key":"721_CR50","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","journal-title":"Ann Intern Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-018-0721-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-018-0721-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-018-0721-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T11:27:32Z","timestamp":1724412452000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-018-0721-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,9]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["721"],"URL":"https:\/\/doi.org\/10.1007\/s12325-018-0721-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2018,6,9]]},"assertion":[{"value":"23 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2018","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}